Black Diamond Therapeutics, Inc. (BDTX) is a clinical-stage precision-oncology biotechnology company, not an exchange-traded fund. Its shares have recently traded near $2, making the $10 level discussed below a demanding, multi-fold move rather than a near-term step.
This analysis reviewed six current, individually attributed analyst price targets. They range from a low of $8 to a high of $14, and their arithmetic mean is approximately $10.33, which rounds to a clean central target of $10. Independent data providers report comparable figures — for example, S&P Global and MarketBeat show averages near $10 to $11 depending on how many analysts are included — so the $10 central target sits comfortably within the published range of estimates rather than at either extreme.
The spread between targets reflects real differences in how analysts weigh clinical risk. Wedbush analyst Robert Driscoll carries the highest target at $14 (raised in March 2026), while Raymond James' Sean McCutcheon and BTIG's Robert Burns are at $11. Jefferies analyst Maury Raycroft holds a $10 target and has described the setup around the company's catalysts as "attractive." More conservative views come from Stifel's Laura Prendergast and Piper Sandler's Kelsey Goodwin, both at $8. The overall stance is broadly constructive — a Moderate Buy to Strong Buy consensus — though Guggenheim downgraded the stock to a Hold in December 2025, underscoring that the bullish case is not unanimous.
BDTX shares have recently traded near $2, with recent closes ranging roughly between $1.70 and $2.10 and the stock down more than 50% over the past year. From about $2, a move to $10 implies upside of approximately 400%, which is best characterized as a very large move. The company generated no product revenue in its latest reported periods and remains a pre-commercial biotech, so the path toward the target is almost entirely dependent on clinical data, regulatory feedback, and its ability to fund and advance silevertinib toward a pivotal trial rather than on near-term earnings momentum.
The central catalyst is silevertinib, which Black Diamond is advancing in non-small cell lung cancer (NSCLC) and glioblastoma. Analysts such as Jefferies and Raymond James have pointed to two key near-term events: longer-term first-line follow-up data in non-classical EGFR-mutant NSCLC and regulatory feedback that could clear the way for a registrational (pivotal) trial. A durable, competitive response rate and tolerability profile would strengthen the case that the company has a "best-in-class" candidate. The balance sheet also matters: the company has reported cash and investments designed to fund operations into 2027, and its latest quarterly loss per share beat expectations, providing some financial breathing room while the pipeline matures.
As a clinical-stage biotech with no marketed product, Black Diamond faces binary risk: disappointing trial data, safety signals, or a delayed or rejected regulatory path could sharply compress the valuation. Competition in EGFR-mutant NSCLC is intense, with multiple established and emerging fourth-generation inhibitors vying for the same patients. Dilution is an ongoing concern, since additional equity raises would weigh on per-share value. The stock's weak relative strength and a technical rating near the bottom of the scale also indicate that the market currently doubts the lofty analyst targets are attainable in the near term.
Meaningful technical levels are limited for a low-priced, pre-revenue clinical-stage name trading near its 52-week low. The recent trading range of roughly $1.70 to $2.10 acts as a near-term reference zone, with the 52-week low serving as a durable support area to monitor. Because the $10 target sits far above any recent resistance, there is no established technical pathway of prior highs to retrace — the move would require sustained positive clinical newsflow and a decisive re-rating by the market rather than a simple breakout above a resistance level.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms may vary and the actual timeline for a clinical-stage company is inherently uncertain. Investors should watch for updated silevertinib efficacy and durability data, U.S. Food and Drug Administration feedback on the registrational path, quarterly cash and operating-expense trends, any partnership or financing announcements, and subsequent analyst target revisions. Because the stock's value is tied to clinical catalysts, earnings dates matter less than data readouts and regulatory updates.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than by scanning charts manually. If you would like to complement fundamental research with automated, data-driven market scanning, exploring the AI Daily Buy/Sell Signals can be a practical next step.
The question of whether BDTX can reach $10 is ultimately a question about whether silevertinib can deliver competitive clinical data and secure a clear path to registration. The $10 central target, derived from the mean of six analyst targets spanning $8 to $14, implies roughly 400% upside from a price near $2 — a very large move that only a decisive clinical or regulatory catalyst could support. Bullish analysts emphasize the drug's early durability signal and a cash runway into 2027, while cautious voices point to no revenue, binary risk, competition, and the stock's weak recent performance. The next data readouts and regulatory updates will be the most important signposts, and no outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BDTX has been loosely correlated with NGEN. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BDTX jumps, then NGEN could also see price increases.
| Ticker / NAME | Correlation To BDTX | 1D Price Change % | ||
|---|---|---|---|---|
| BDTX | 100% | +0.94% | ||
| NGEN - BDTX | 47% Loosely correlated | +1.50% | ||
| MLTX - BDTX | 42% Loosely correlated | +7.56% | ||
| MLYS - BDTX | 39% Loosely correlated | +4.12% | ||
| NAMS - BDTX | 39% Loosely correlated | +8.03% | ||
| REPL - BDTX | 39% Loosely correlated | -6.44% | ||
More | ||||